Compounded Semaglutide vs. Ozempic: What Is Different?

Ozempic is a specific FDA-approved semaglutide product. “Compounded semaglutide” describes a preparation made through compounding; it is not the name of one standardized, approved product. Sharing an ingredient description does not establish that two offers have the same approval, formulation or supporting evidence.

This is an educational comparison, not a recommendation to start, stop or switch a medicine. Product-specific questions belong with your prescriber and dispensing pharmacist.

Compare the product, not just the ingredient

Question	Ozempic	A compounded semaglutide preparation
What is it?	A named semaglutide medicine with an official label	A preparation whose exact details must be obtained from the prescriber and pharmacy
Is the finished product FDA-approved?	Yes	Compounded drugs are not FDA-approved
Which information applies?	The current Ozempic prescribing information	The actual preparation’s identity, ingredients, concentration, labeling and instructions
Can the name alone settle equivalence?	A brand identifies a particular product	The word semaglutide alone does not establish equivalence to the brand

Sources: Ozempic prescribing information, FDA compounding Q&A.

Ozempic’s approved uses concern specific patients with type 2 diabetes; consult its current label for the full indications and restrictions. It is not the same branded product as Wegovy. Neither brand name should be treated as a generic promise of weight-loss suitability. Ozempic label.

What FDA says about compounding

Compounding can address an individual medical need when an approved drug is not appropriate. However, compounded medicines do not receive FDA premarket review for safety, effectiveness and quality. Their legal and clinical context is different from that of an approved generic medicine. FDA Q&A.

A broad statement such as “compounded semaglutide is always permitted” does not resolve a particular offer. Current rules, the compounder, the patient-specific circumstances and the actual preparation matter. Ask the clinician and pharmacy to explain the basis for what they are proposing.

Ingredients and instructions deserve attention

FDA warns that semaglutide sodium and semaglutide acetate are different active ingredients from the one used in approved drugs. The agency also reports dosing errors with compounded injectable GLP-1 products, including errors involving concentrations, measuring devices and calculations. FDA GLP-1 safety information.

Those concerns are reasons to obtain clear product-specific instructions from a qualified professional. They are not an invitation to calculate a conversion using an online chart. If the label or instructions are unclear, contact the dispensing pharmacist or prescriber before using the product.

Questions for your prescriber and pharmacist

Bring the actual offer or label to the discussion. Ask:

• What is the exact active ingredient, and are other ingredients added?
• Why is this particular preparation being considered for me?
• Which licensed pharmacy will dispense it, and how can I verify that identity?
• What evidence supports the proposed use and the actual formulation?
• How will I receive and confirm the instructions, storage requirements and contact details?
• Who handles a problem with the shipment, label or medicine?

You can also ask how an approved alternative would compare for your circumstances. FDA explains that approved generics follow an approval pathway; a compounded product should not be described as an FDA-approved generic merely because it contains a similarly named ingredient. FDA approved-drug Q&A.

Put price in the right context

Request an itemized quote for the exact product and follow-up service. Avoid comparing a medication-only price with a package that includes clinical visits, or assuming that a price difference proves equivalence or quality.

Use the cost worksheet and clinician checklist to organize the conversation. The purpose is a clearer decision with your care team, not a self-directed substitution.

Sources and further reading

1. FDA: concerns with unapproved GLP-1 medicines (opens in a new tab)
2. FDA: compounding questions and answers (opens in a new tab)
3. Ozempic: official prescribing information (opens in a new tab)
4. FDA: approved drugs questions and answers (opens in a new tab)

Sources were checked on October 7, 2026. Prices, labels and policies can change. Linked studies being peer reviewed does not mean this article has been clinically reviewed.